NK cells and cancer: you can teach innate cells new tricks (original) (raw)

• Artis, D. & Spits, H. The biology of innate lymphoid cells. Nature 517, 293–301 (2015).
  Article CAS PubMed Google Scholar
• Orange, J. S. Natural killer cell deficiency. J. Allergy Clin. Immunol. 132, 515–525 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Campbell, K. S. & Purdy, A. K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132, 315–325 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schenkel, A. R., Kingry, L. C. & Slayden, R. A. The Ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. Front. Immunol. 4, 90 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L. & Phillips, J. H. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 157, 4741–4745 (1996).
  CAS PubMed Google Scholar
• Wada, H., Matsumoto, N., Maenaka, K., Suzuki, K. & Yamamoto, K. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues. Eur. J. Immunol. 34, 81–90 (2004).
  Article CAS PubMed Google Scholar
• Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799 (1998).
  Article CAS PubMed Google Scholar
• Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199–5204 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. Mouse CD94/NKG2A Is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) Class I molecule Qa-1b. J. Exp. Med. 188, 1841–1848 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Lopez-Vergès, S. et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725–14732 (2011).
  Article PubMed PubMed Central Google Scholar
• Cassidy, S. A., Cheent, K. S. & Khakoo, S. I. Effects of peptide on NK cell-mediated MHC I recognition. Front. Immunol. 5, 133 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Tripathy, S. K., Smith, H. R. C., Holroyd, E. A., Pingel, J. T. & Yokoyama, W. M. Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I. J. Virol. 80, 545–550 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44–49 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–729 (1999).
  Article CAS PubMed Google Scholar
• Lanier, L. L. NKG2D receptor and its ligands in host defense. Cancer Immunol. Res. 3, 575–582 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. & Jung, H. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31, 413–441 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kruse, P. H., Matta, J., Ugolini, S. & Vivier, E. Natural cytotoxicity receptors and their ligands. Immunol. Cell Biol. 92, 221–229 (2014).
  Article CAS PubMed Google Scholar
• Pende, D. et al. Identification and molecular characterization of Nkp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505–1516 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Pessino, A. et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953–960 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Cantoni, C. et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J. Exp. Med. 189, 787–796 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl Acad. Sci. USA 104, 3384–3389 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hollyoake, M., Campbell, R. D. & Aguado, B. NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol. Biol. Evol. 22, 1661–1672 (2005).
  Article CAS PubMed Google Scholar
• Martinet, L. & Smyth, M. J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243–254 (2015).
  Article CAS PubMed Google Scholar
• Lakshmikanth, T. et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251–1263 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Iguchi-Manaka, A. et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205, 2959–2964 (2008). This article provides evidence that the DNAM1 receptor has an important role in immune surveillance of tumour development.
  Article CAS PubMed PubMed Central Google Scholar
• Gilfillan, S. et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965–2973 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, C. J. et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15, 431–438 (2014).
  Article CAS PubMed Google Scholar
• Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26, 923–937 (2014). References 28 and 29 demonstrate the role of DNAM1, CD96 and TIGIT in the regulation of NK cell and T cell responses against tumours.
  Article CAS PubMed Google Scholar
• Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).
  Article CAS PubMed Google Scholar
• Battella, S., Cox, M. C., Santoni, A. & Palmieri, G. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J. Leukoc. Biol., http://dx.doi.org/10.1189/jlb.5VMR0415-141R (2015).
• Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388–400 (2015).
  Article CAS PubMed Google Scholar
• Krzewski, K. & Coligan, J. E. Human NK cell lytic granules and regulation of their exocytosis. NK Cell Biol. 3, 335 (2012).
  Google Scholar
• Wallin, R. P. A., Screpanti, V., Michaëlsson, J., Grandien, A. & Ljunggren, H.-G. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur. J. Immunol. 33, 2727–2735 (2003).
  Article CAS PubMed Google Scholar
• Smyth, M. J. et al. Activation of NK cell cytotoxicity. Mol. Immunol. 42, 501–510 (2005).
  Article CAS PubMed Google Scholar
• Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356–1361 (2002).
  Article CAS PubMed Google Scholar
• Cooper, M. A. et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97, 3146–3151 (2001).
  Article CAS PubMed Google Scholar
• Maghazachi, A. A. in The Chemokine System in Experimental and Clinical Hematology (ed. Bruserud, O.) 37–58 (Springer, 2010).
  Book Google Scholar
• O'Sullivan, T. et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209, 1869–1882 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Roder, J. C. et al. A new immunodeficiency disorder in humans involving NK cells. Nature 284, 553–555 (1980).
  Article CAS PubMed Google Scholar
• Sullivan, J. L., Byron, K. S., Brewster, F. E. & Purtilo, D. T. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science 210, 543–545 (1980).
  Article CAS PubMed Google Scholar
• Talmadge, J. E., Meyers, K. M., Prieur, D. J. & Starkey, J. R. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J. Natl Cancer Inst. 65, 929–935 (1980).
  CAS PubMed Google Scholar
• Gorelik, E., Wiltrout, R. H., Okumura, K., Habu, S. & Herberman, R. B. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer 30, 107–112 (1982).
  Article CAS PubMed Google Scholar
• Nakajima, T., Mizushima, N., Nakamura, J. & Kanai, K. Surface markers of NK cells in peripheral blood of patients with cirrhosis and hepatocellular carcinoma. Immunol. Lett. 13, 7–10 (1986).
  Article CAS PubMed Google Scholar
• Pross, H. F. & Lotzová, E. Role of natural killer cells in cancer. Nat. Immunol. 12, 279–292 (1993).
  CAS Google Scholar
• Schantz, S. P., Shillitoe, E. J., Brown, B. & Campbell, B. Natural killer cell activity and head and neck cancer: a clinical assessment. J. Natl Cancer Inst. 77, 869–875 (1986).
  CAS PubMed Google Scholar
• Strayer, D. R., Carter, W. A. & Brodsky, I. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. Breast Cancer Res. Treat. 7, 187–192 (1986).
  Article CAS PubMed Google Scholar
• Hersey, P., Edwards, A., Honeyman, M. & McCarthy, W. H. Low natural-killer-cell activity in familial melanoma patients and their relatives. Br. J. Cancer 40, 113–122 (1979).
  Article CAS PubMed PubMed Central Google Scholar
• Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795–1799 (2000). This is a clinical study correlating susceptibility to cancer and NK cell function.
  Article CAS PubMed Google Scholar
• Spinner, M. A. et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity. Blood 123, 809–821 (2013).
  Article CAS PubMed Google Scholar
• Gineau, L. et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122, 821–832 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Smyth, M. J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2, 850–861 (2002).
  Article CAS PubMed Google Scholar
• Bezman, N. A. et al. Molecular definition of the identity and activation of natural killer cells. Nat. Immunol. 13, 1000–1009 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hudspeth, K., Silva-Santos, B. & Mavilio, D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. NK Cell Biol. 4, 69 (2013).
  Google Scholar
• Robinette, M. L. et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306–317 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Albertsson, P. A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24, 603–609 (2003).
  Article CAS PubMed Google Scholar
• Bix, M. et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 349, 329–331 (1991).
  Article CAS PubMed Google Scholar
• Nausch, N. & Cerwenka, A. NKG2D ligands in tumor immunity. Oncogene 27, 5944–5958 (2008).
  Article CAS PubMed Google Scholar
• Cerwenka, A., Baron, J. L. & Lanier, L. L. Ectopic expression of retinoic acid early inducible-1 gene (_RAE_-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl Acad. Sci. USA 98, 11521–11526 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Diefenbach, A., Jensen, E. R., Jamieson, A. M. & Raulet, D. H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413, 165–171 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Guerra, N. et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571–580 (2008). This article provides evidence for the role of NKG2D in tumour immunosurveillance in mouse tumour models.
  Article CAS PubMed PubMed Central Google Scholar
• Hayakawa, Y. et al. Cutting edge: tumor rejection mediated by NKG2D receptor–ligand interaction is dependent upon perforin. J. Immunol. 169, 5377–5381 (2002).
  Article CAS PubMed Google Scholar
• Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734–738 (2002).
  Article CAS PubMed Google Scholar
• Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482–486 (2007).
  Article CAS PubMed Google Scholar
• Salih, H. R., Rammensee, H.-G. & Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169, 4098–4102 (2002).
  Article CAS PubMed Google Scholar
• Wu, J. D. et al. Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114, 560–568 (2004). References 63–66 describe mechanisms by which tumours shed NKG2DLs to avoid NK cell and T cell recognition.
  Article CAS PubMed PubMed Central Google Scholar
• Fernández-Messina, L. et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J. Biol. Chem. 285, 8543–8551 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Salih, H. R., Goehlsdorf, D. & Steinle, A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum. Immunol. 67, 188–195 (2006).
  Article CAS PubMed Google Scholar
• Salih, H. R., Holdenrieder, S. & Steinle, A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13, 3448–3456 (2008).
  Article CAS PubMed Google Scholar
• Holdenrieder, S. et al. Soluble MICA in malignant diseases. Int. J. Cancer 118, 684–687 (2006).
  Article CAS PubMed Google Scholar
• Crane, C. A. et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc. Natl Acad. Sci. USA 111, 12823–12828 (2014). This article shows that the secretion of lactate dehydrogenase by human glioblastomas induces NKG2D ligands on monocytes, which may serve as decoys to evade antitumour immune responses.
  Article CAS PubMed PubMed Central Google Scholar
• Champsaur, M. & Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267–285 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Oppenheim, D. E. et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6, 928–937 (2005).
  Article CAS PubMed Google Scholar
• Deng, W. et al. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348, 136–139 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Kopp, H.-G., Placke, T. & Salih, H. R. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69, 7775–7783 (2009).
  Article CAS PubMed Google Scholar
• Placke, T., Kopp, H.-G. & Salih, H. R. The wolf in sheep's clothing. Oncoimmunology 1, 557–559 (2012).
  Article PubMed PubMed Central Google Scholar
• Placke, T., Salih, H. R. & Kopp, H.-G. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J. Immunol. 189, 154–160 (2012).
  Article CAS PubMed Google Scholar
• Placke, T., Kopp, H.-G. & Salih, H. R. Modulation of natural killer cell anti-tumor reactivity by platelets. J. Innate Immun. 3, 374–382 (2011).
  Article CAS PubMed Google Scholar
• Wilson, E. B. et al. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 6, e22842 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Holt, D., Ma, X., Kundu, N. & Fulton, A. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4. Cancer Immunol. Immunother. 60, 1577–1586 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pietra, G. et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72, 1407–1415 (2012).
  Article CAS PubMed Google Scholar
• Hoskin, D., Mader, J., Furlong, S., Conrad, D. & Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 32, 527–535 (2008).
  CAS PubMed Google Scholar
• Richards, J. O. et al. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 108, 246–252 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Mocellin, S., Marincola, F. M. & Young, H. A. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78, 1043–1051 (2005).
  Article CAS PubMed Google Scholar
• Park, J. Y. et al. IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Mol. Cells 32, 265–272 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Moretta, A. et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197–223 (2001).
  Article CAS PubMed Google Scholar
• Byrd, A., Hoffmann, S. C., Jarahian, M., Momburg, F. & Watzl, C. Expression analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLoS ONE 2, e1339 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Cagnano, E. et al. Expression of ligands to NKp46 in benign and malignant melanocytes. J. Invest. Dermatol. 128, 972–979 (2007).
  Article CAS PubMed Google Scholar
• Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495–1503 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Y., Wang, Q. & Mariuzza, R. A. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 208, 703–714 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Matta, J. et al. Induction of B7-H6, a ligand for the natural killer cell–activating receptor NKp30, in inflammatory conditions. Blood 122, 394–404 (2013).
  Article CAS PubMed Google Scholar
• Halfteck, G. G. et al. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 182, 2221–2230 (2009).
  Article CAS PubMed Google Scholar
• Glasner, A. et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 188, 2509–2515 (2012).
  Article CAS PubMed Google Scholar
• Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827–1834 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  Article CAS PubMed Google Scholar
• Smyth, M. J. et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202, 583–588 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Elboim, M. et al. Tumor immunoediting by NKp46. J. Immunol. 184, 5637–5644 (2010).
  Article CAS PubMed Google Scholar
• Alvarez, I. B. et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J. Infect. Dis. 202, 524–532 (2010).
  Article CAS PubMed Google Scholar
• Norris, S. et al. PD-1 expression on natural killer cells and CD8+ T cells during chronic HIV-1 infection. Viral Immunol. 25, 329–332 (2012).
  Article CAS PubMed Google Scholar
• Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. & Cerwenka, A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells. J. Immunol. 192, 4184–4191 (2014).
  Article CAS PubMed Google Scholar
• Benson, D. M. et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood 116, 2286–2294 (2010). This is a report of the expression of PD1 on NK cells and augmentation of NK cell activity against multiple myeloma by blockade of PD1.
  Article CAS PubMed PubMed Central Google Scholar
• Boyerinas, B. et al. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. Cancer Immunol. Res. 3, 1148–1157 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Lang, S., Vujanovic, N. L., Wollenberg, B. & Whiteside, T. L. Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur. J. Immunol. 28, 780–786 (1998).
  Article CAS PubMed Google Scholar
• Chambers, B. J., Salcedo, M. & Ljunggren, H.-G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5, 311–317 (1996).
  Article CAS PubMed Google Scholar
• Contardi, E. et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 117, 538–550 (2005).
  Article CAS PubMed Google Scholar
• Laurent, S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J. Transl Med. 11, 108 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Jarahian, M. et al. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J. Virol. 83, 8108–8121 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bhat, R., Dempe, S., Dinsart, C. & Rommelaere, J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 128, 908–919 (2011).
  Article CAS PubMed Google Scholar
• Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl Med. 6, 226ra32 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Romagné, F. et al. Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells. Blood 114, 2667–2677 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Vahlne, G. et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur. J. Immunol. 40, 813–823 (2010).
  Article CAS PubMed Google Scholar
• Kohrt, H. E. et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123, 678–686 (2014). This article reports that KIR blockade enhances the ADCC activity of NK cells in preclinical models.
  Article CAS PubMed PubMed Central Google Scholar
• Vey, N. et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317–4323 (2012).
  Article CAS PubMed Google Scholar
• Benson, D. M. et al. A Phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 21, 4055–4061 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Benson, D. M. et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324–4333 (2012). References 113–115 report Phase I and II trials with KIR blockade in cancer patients.
  Article CAS PubMed PubMed Central Google Scholar
• Seymour, L., Tinker, A., Hirte, H., Wagtmann, N. & Dodion, P. Abstract O3.2. Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Ann. Oncol. 26(Suppl 2), ii3–ii3 (2015).
  Article Google Scholar
• Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734–3743 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, H., Sun, C. & Xiao, W. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine 65, 33–41 (2014).
  Article CAS PubMed Google Scholar
• Jing, W. et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J. Immunother. Cancer 3, 2 (2015).
  Article PubMed PubMed Central Google Scholar
• Ngiow, S. F., Teng, M. W. L. & Smyth, M. J. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71, 6567–6571 (2011).
  Article CAS PubMed Google Scholar
• Woo, S.-R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).
  Article CAS PubMed Google Scholar
• Bartkowiak, T. & Curran, M. A. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front. Oncol. 5, 117 (2015).
  Article PubMed PubMed Central Google Scholar
• Baessler, T. et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 115, 3058–3069 (2010).
  Article CAS PubMed Google Scholar
• Kohrt, H. E. et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122, 1066–1075 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kohrt, H. E. et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423–2432 (2011). References 124 and 125 demonstrate that agonist CD137 antibodies enhance NK cell-mediated ADCC in preclinical models.
  Article CAS PubMed PubMed Central Google Scholar
• Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X. & Melero, I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508–516 (2010).
  Article CAS PubMed Google Scholar
• Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F. & Wolchok, J. D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19, 1044–1053 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
  Article CAS PubMed Google Scholar
• Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100 (2002). This article supplies the first evidence that KIR-mismatched NK cells decrease leukaemia relapse in human patients receiving haematopoietic stem cell transplants.
  Article CAS PubMed Google Scholar
• Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051–3057 (2005). This article reports on the adoptive transfer of allogeneic NK cells in patients with leukaemia.
  Article CAS PubMed Google Scholar
• Ishikawa, E. et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24, 1861–1871 (2004).
  PubMed Google Scholar
• Shah, N. N. et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood 125, 784–792 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106, 1915–1919 (2009).
  Article PubMed PubMed Central Google Scholar
• Ni, J., Miller, M., Stojanovic, A. & Cerwenka, A. Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology 2 (2013).
• Ni, J., Miller, M., Stojanovic, A., Garbi, N. & Cerwenka, A. Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors. J. Exp. Med. 209, 2351–2365 (2012). This article reports that adoptive transfer of cytokine-activated mouse NK cells shows efficacy against tumours in vivo.
  Article CAS PubMed PubMed Central Google Scholar
• Ardolino, M., Hsu, J. & Raulet, D. H. Cytokine treatment in cancer immunotherapy. Oncotarget 6, 19346–19347 (2015).
  Article PubMed PubMed Central Google Scholar
• Ardolino, M. et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 124, 4781–4794 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Floros, T. & Tarhini, A. A. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin. Oncol. 42, 539–548 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, Y. et al. IL-15 superagonist–mediated immunotoxicity: role of NK cells and IFN-γ. J. Immunol. 195, 2353–2364 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Glienke, W. et al. Advantages and applications of CAR-expressing natural killer cells. Exp. Pharmacol. Drug Discov. 6, 21 (2015).
  Google Scholar
• Hermanson, D. L. & Kaufman, D. S. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front. Immunol. 6, 195 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Boissel, L., Betancur, M., Wels, W. S., Tuncer, H. & Klingemann, H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 33, 1255–1259 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Müller, T. et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57, 411–423 (2007).
  Article CAS PubMed Google Scholar
• Esser, R. et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J. Cell. Mol. Med. 16, 569–581 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ahmed, M. & Cheung, N.-K. V. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588, 288–297 (2014).
  Article CAS PubMed Google Scholar
• Uherek, C. et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100, 1265–1273 (2002).
  CAS PubMed Google Scholar
• Liu, H. et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK92 cells. Oncol. Rep. 33, 95–102 (2015).
  CAS PubMed Google Scholar
• Schönfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 23, 330–338 (2015).
  Article CAS PubMed Google Scholar
• Sahm, C., Schönfeld, K. & Wels, W. S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol. Immunother. 61, 1451–1461 (2012).
  Article CAS PubMed Google Scholar
• Zhang, G. et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol. Cell Biol. 91, 615–624 (2013).
  Article CAS PubMed Google Scholar
• Töpfer, K. et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J. Immunol. 194, 3201–3212 (2015).
  Article CAS PubMed Google Scholar
• Jiang, H. et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8, 297–310 (2014).
  Article CAS PubMed Google Scholar
• Knorr, D. A. & Kaufman, D. S. Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl. Res. J. Lab. Clin. Med. 156, 147–154 (2010).
  Article CAS Google Scholar
• Eguizabal, C. et al. Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. NK Cell Biol. 5, 439 (2014).
  Google Scholar
• Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917–927 (2014).
  Article CAS PubMed Google Scholar
• Ni, Z. et al. Functional chimeric antigen receptor-expressing natural killer cells derived from human pluripotent stem cells. Blood 122, 896–896 (2013).
  Google Scholar
• Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376–383 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Li, L. et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17, 147–154 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shimasaki, N. et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14, 830–840 (2012).
  Article CAS PubMed Google Scholar
• Alsamah, W. & Romia, Y. Modification of natural killer cells to target tumors. Int. J. Pharm. Clin. Res. 6, 97–100 (2014).
  Google Scholar
• Altvater, B. et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15, 4857–4866 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Müller, N. et al. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J. Immunother. 38, 197–210 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Han, J. et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015).
  Article PubMed PubMed Central Google Scholar
• Boissel, L. et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2 (2013).
• Klingemann, H. Are natural killer cells superior CAR drivers? OncoImmunology 3, e28147 (2014).
  Article PubMed PubMed Central Google Scholar
• Sentman, C. L. & Meehan, K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156–159 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Barber, A., Rynda, A. & Sentman, C. L. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J. Immunol. 183, 6939–6947 (2009).
  Article CAS PubMed Google Scholar
• Roy, S. et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 180, 1729–1736 (2008).
  Article CAS PubMed Google Scholar
• Zhang, T. & Sentman, C. L. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 71, 2066–2076 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lehner, M. et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS ONE 7, e31210 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• VanSeggelen, H. et al. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol. Ther. http://dx.doi.org/10.1038/mt.2015.119 (2015).
• Kudo, K. et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74, 93–103 (2014).
  Article CAS PubMed Google Scholar
• Tal, Y. et al. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget 5, 10949–10958 (2014).
  Article PubMed PubMed Central Google Scholar
• Zhang, T., Wu, M.-R. & Sentman, C. L. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J. Immunol. 189, 2290–2299 (2012).
  Article CAS PubMed Google Scholar
• Asano, R. et al. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system. FEBS J. 279, 223–233 (2012).
  Article CAS PubMed Google Scholar
• Reusch, U. et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 6, 727–738 (2014).
  Article PubMed Central Google Scholar
• Kellner, C. et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett. 303, 128–139 (2011).
  Article CAS PubMed Google Scholar
• Bruenke, J. et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells. Br. J. Haematol. 125, 167–179 (2004).
  Article CAS PubMed Google Scholar
• Hartmann, F. et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease role of infusion schedule and costimulation with cytokines. Clin. Cancer Res. 7, 1873–1881 (2001).
  CAS PubMed Google Scholar
• Kasuya, K. et al. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer. Int. J. Mol. Med. 25, 209–215 (2010).
  CAS PubMed Google Scholar
• Shahied, L. S. et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279, 53907–53914 (2004).
  Article CAS PubMed Google Scholar
• Singer, H. et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16: J. Immunother. 33, 599–608 (2010).
  Article CAS PubMed Google Scholar
• Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844–3855 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 28, 274–282 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Spear, P., Wu, M.-R., Sentman, M.-L. & Sentman, C. L. NKG2D ligands as therapeutic targets. Cancer Immun. 13, 8 (2013).
  PubMed PubMed Central Google Scholar
• Strandmann, E. P. von et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107, 1955–1962 (2006).
  Article CAS Google Scholar
• Rothe, A. et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int. J. Cancer 134, 2829–2840 (2014).
  Article CAS PubMed Google Scholar
• Germain, C. et al. MHC Class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin. Cancer Res. 11, 7516–7522 (2005).
  Article CAS PubMed Google Scholar
• Stamova, S. et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 25, 1053–1056 (2011).
  Article CAS PubMed Google Scholar